MPLT MapLight Therapeutics, Inc.
USHealthcareAs of 2026-08-04
Why MPLT matters now
MapLight Therapeutics, Inc. (MPLT) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.94 with +3.11% on the session and $551.5M in market capitalization; recent performance reads 1-month +6.43% and YTD +64.03%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-60.7M, and EPS of $-1.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -722.1%.
The latest indexable market news headline is "MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $44.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.26
P/S
0.00
EV/EBITDA
0.14
DCF Value
$0.93
FCF Yield
-722.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-69.1%
ROA
-47.6%
ROIC
-51.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-60.7M | $-1.34 |
| Q4 2025 | $0.00 | $-79.5M | $-1.81 |
| FY 2025 | $0.00 | $-161.2M | $-3.66 |
| Q3 2025 | $0.00 | $-29.4M | $-0.71 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.00
Target (Median)
$44.00
Target Range
$36.00 - $48.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.34
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.